Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives $15.39 Average Price Target from Analysts

Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) have been given a consensus rating of “Hold” by the thirteen research firms that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, nine have issued a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $15.3889.

FOLD has been the topic of a number of research analyst reports. Needham & Company LLC lowered shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, December 19th. TD Cowen downgraded Amicus Therapeutics from a “buy” rating to a “hold” rating and set a $14.50 price objective for the company. in a report on Monday, December 22nd. Citigroup reaffirmed a “neutral” rating and issued a $14.50 target price (down from $17.00) on shares of Amicus Therapeutics in a research report on Monday, December 22nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Amicus Therapeutics in a report on Monday, December 29th. Finally, Guggenheim downgraded Amicus Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 5th.

Insider Buying and Selling at Amicus Therapeutics

In other news, CEO Bradley L. Campbell sold 75,000 shares of the business’s stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $14.31, for a total transaction of $1,073,250.00. Following the completion of the sale, the chief executive officer owned 1,021,180 shares in the company, valued at approximately $14,613,085.80. The trade was a 6.84% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 2.20% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Osaic Holdings Inc. grew its stake in Amicus Therapeutics by 450.1% during the second quarter. Osaic Holdings Inc. now owns 4,104 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 3,358 shares during the period. EverSource Wealth Advisors LLC raised its stake in shares of Amicus Therapeutics by 472.6% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 4,455 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 3,677 shares during the period. Farther Finance Advisors LLC raised its stake in shares of Amicus Therapeutics by 2,651.5% in the 4th quarter. Farther Finance Advisors LLC now owns 1,871 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 1,803 shares during the period. GAMMA Investing LLC lifted its holdings in shares of Amicus Therapeutics by 167.1% during the 4th quarter. GAMMA Investing LLC now owns 1,987 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 1,243 shares in the last quarter. Finally, Strs Ohio acquired a new position in shares of Amicus Therapeutics during the 1st quarter valued at $30,000.

Amicus Therapeutics Trading Up 0.3%

NASDAQ FOLD opened at $14.43 on Monday. The company has a market cap of $4.53 billion, a P/E ratio of -180.38 and a beta of 0.43. Amicus Therapeutics has a 12 month low of $5.51 and a 12 month high of $14.43. The company has a debt-to-equity ratio of 1.43, a current ratio of 2.84 and a quick ratio of 1.88. The company has a 50-day moving average of $14.33 and a 200-day moving average of $11.38.

Amicus Therapeutics (NASDAQ:FOLD) last released its earnings results on Friday, February 20th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.13 by ($0.03). Amicus Therapeutics had a positive return on equity of 4.15% and a negative net margin of 4.27%.The company had revenue of $185.21 million during the quarter, compared to analyst estimates of $185.00 million. During the same period in the prior year, the business posted $0.09 earnings per share. Amicus Therapeutics’s revenue was up 23.7% on a year-over-year basis. As a group, equities analysts predict that Amicus Therapeutics will post 0.15 earnings per share for the current year.

About Amicus Therapeutics

Amicus Therapeutics (NASDAQ:FOLD) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for rare and orphan diseases. The company specializes in pharmacological chaperones and gene therapy approaches designed to address the underlying causes of lysosomal storage disorders. Its proprietary technology platform integrates structure‐based drug design with precision medicine to identify small molecules that stabilize misfolded proteins and restore cellular function.

The company’s lead marketed product, Galafold (migalastat), is an oral pharmacological chaperone approved in the United States, European Union and other territories for the treatment of Fabry disease in patients with amenable genetic variants.